Day One Biopharmaceuticals secured a research and licensing deal with Sprint Bioscience in a bid to build out its cancer-fighting arsenal.
The Bay Area biotech is paying $3 million upfront for the global rights of one of Sprint’s cancer programs known as VADA, which is designed…
Click here to view original post
